149,261 members

Skip to content. | Skip to navigation

News

NICE encourages further discussions on Kymriah for adult lymphoma

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

NICE encourages further discussions on Kymriah for adult lymphoma

CAR-T is too expensive to recommend as a treatment for adults with lymphoma, NICE says in draft guidance published this week.

However, NICE does recognise that Novartis’ tisagenlecleucel-T, also known as Kymriah, has significant clinical benefits, and would welcome further discussions on its cost-effectiveness.

NICE’s independent technology appraisal committee considered tisagenlecleucel-T for adults who have relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. More…